Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

• Published in: GeroScience 2021-10, Vol.43 (5), p.2321-2331
• Main Authors: Vályi-Nagy, István, Matula, Zsolt, Gönczi, Márton, Tasnády, Szabolcs, Bekő, Gabriella, Réti, Marienn, Ajzner, Éva, Uher, Ferenc
• Format: Article
• Language: English
• Subjects: Adaptive immunity; Antibodies; Biomedical and Life Sciences; BNT162 Vaccine; Cell Biology; COVID-19; COVID-19 Vaccines; Epitopes; Geriatrics/Gerontology; Humans; Immune response (cell-mediated); Immune response (humoral); Immunoglobulin A; Immunoglobulin G; Life Sciences; Lymphocytes; Lymphocytes T; Molecular Medicine; mRNA; Nucleocapsids; Original; Original Article; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike protein; T-Lymphocytes; Vaccines; Viruses; γ-Interferon
• ISSN: 2509-2715; 2509-2723
• DOI: 10.1007/s11357-021-00471-6

In the present study, humoral and T cell-mediated immune responses elicited by BBIBP-CorV (inactivated virus) and BNT162b2 (mRNA-based) vaccines against SARS-CoV-2 virus were compared. Convalescent volunteers were also investigated to evaluate adaptive immunity induced by live virus. Although both vaccines induced antibody- and T cell-mediated immune responses, our analysis revealed significant quantitative and qualitative differences between the two types of challenges. The BBIBP-CorV vaccine elicited antireceptor-binding domain (RBD) IgG, as well as anti-spike protein (S) IgG and IgA antibodies in healthy individuals, the levels of which were much lower than after BNT162b2 vaccination but still higher than in the convalescent patients. The cumulative IFNγ-positive T cell response, however, was only twofold higher in participants injected with BNT162b2 compared to those who were primed and boosted with BBIBP-CorV vaccine. Moreover, the inactivated virus vaccine induced T cell response that targets not only the S but also the nucleocapsid (N) and membrane (M) proteins, whereas the mRNA vaccine was able to elicit a much narrower response that targets the S protein epitopes only. Thus, the pattern of BBIBP-CorV-induced T cell response in virus-naive participants was similar to the cell-mediated anti-SARS-CoV-2 response observed in convalescent patients. Based on these data, we can conclude that the BBIBP-CorV inactivated virus vaccine is immunologically effective. However, the duration of BBIBP-CorV-induced integrated, antibody, and T cell-mediated, immune responses needs further investigation.